Phase 2
Completed N=30
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
Advanced or Metastatic Solid Tumors · Advanced or Metastatic Breast Cancer
Source: ClinicalTrials.gov NCT00748553 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcomePrimary: Phase I: Percentage of Participants Responding to Treatment — 61.5 percent of participants with response
Summary
The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response. All patients enrolling in this study will receive treatment with Abraxane and Vidaza. Safety will be assessed by adverse events, laboratory results and performance status. Tumor response will be measured by RECIST criteria.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Phase I: Percentage of Participants Responding to Treatment |
61.5 | — |
| PRIMARY Phase II: Percentage of Participants With Objective Response Rate (ORR) Measured Using RECIST 1.0 Criteria |
53.8 | — |
| SECONDARY Number of Participants With ER+ Status |
11 | — |
| SECONDARY Progression-free Survival |
— | — |
Eligibility Criteria
Inclusion Criteria
- For phase I, any solid tumors, including lymphoma, that progressed or were stable as best response on at least one previous therapy and are evaluable.
- For phase II, pathologically confirmed breast cancer, measurable disease, no prior treatments for recurrent or metastatic breast cancer.
- Her-2/neu negative (Phase II)
- Negative pregnancy test for female subjects
- Women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with azacitidine or nab-paclitaxel. investigator.
- Male or female for phase I and female for phase II, >19 years of age and any race.
Exclusion Criteria
- Major surgery, radiotherapy, chemotherapy or investigational agents within 4 weeks of treatment day 1
- Known brain metastases
- Prior taxanes (except for adjuvant therapy more than 6 months prior to treatment day 1) (phase II)
- Active infection requiring antibiotic therapy
- History of allergy or hypersensitivity to nab-paclitaxel, albumin or a taxane
- Grade 2 or greater motor or sensory neuropathy
- Prior cytotoxic chemotherapy for recurrent or metastatic breast cancer (phase II portion)
- Uncontrolled hypertension, arrhythmia, congestive heart failure or angina. Patients who have had a myocardial infarction or cardiac surgery should be at least 6 months from the event and free of active symptoms.
- Known or suspected hypersensitivity to azacitidine or mannitol
- Pregnant or breast feeding
- Patients with advanced malignant hepatic tumors
- Malignancy other than breast carcinoma (phase II)
- Known HIV infection or chronic hepatitis B or C
Data sourced from ClinicalTrials.gov (NCT00748553). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.